Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Lei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7242-5292; OpenAlex author ID A5100433828. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Selective AUTAC-mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.70848↗
  2. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  3. Rapid sample preparation workflow based on enzymatic nanoreactors for potential serum biomarker discovery in pancreatic cancer. Co-author DOI 10.1016/j.talanta.2021.123018↗
  4. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Co-author DOI 10.1080/15384101.2021.2014254↗
  5. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Last author DOI 10.21037/atm-22-1946↗
  6. LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients. First author DOI 10.1007/s13402-017-0360-6↗
  7. Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway. Co-author DOI 10.3892/mmr.2017.6144↗
  8. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. First author DOI 10.3892/ol.2014.2628↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenhui Lou · 3 shared papers, 2022–2023 · strength 0.51
  2. Tiantao Kuang · 3 shared papers, 2015–2022 · strength 0.40
  3. Zihan Zhang · 1 shared paper, 2026 · strength 0.39
  4. Wenchuan Wu · 2 shared papers, 2022–2023 · strength 0.33
  5. Dayong Jin · 3 shared papers, 2015–2022 · strength 0.32
  6. Yefei Rong · 2 shared papers, 2015–2022 · strength 0.24
  7. Xuefeng Xu · 2 shared papers, 2015–2022 · strength 0.22
  8. Dansong Wang · 2 shared papers, 2015–2022 · strength 0.22
  9. Jianang Li · 1 shared paper, 2022 · strength 0.19
  10. Weilin Mao · 1 shared paper, 2022 · strength 0.19
  11. Zhe Wang · 1 shared paper, 2022 · strength 0.16
  12. Chenye Shi · 1 shared paper, 2023 · strength 0.16
  13. Liang Liu · 1 shared paper, 2023 · strength 0.16
  14. Ning Pu · 1 shared paper, 2023 · strength 0.16
  15. Huaxiang Xu · 1 shared paper, 2023 · strength 0.16
  16. Hanlin Yin · 1 shared paper, 2023 · strength 0.16
  17. Wenquan Wang · 1 shared paper, 2023 · strength 0.16
  18. Qiangda Chen · 1 shared paper, 2023 · strength 0.16
  19. Jun Yu · 1 shared paper, 2023 · strength 0.16
  20. Chenxin Zhu · 1 shared paper, 2022 · strength 0.16
  21. Xiaohui Liu · 1 shared paper, 2022 · strength 0.16
  22. Hengchao Li · 1 shared paper, 2022 · strength 0.16
  23. Yueting Xiong · 1 shared paper, 2022 · strength 0.16
  24. Pengyuan Yang · 1 shared paper, 2022 · strength 0.16
  25. Yuan Fang · 1 shared paper, 2017 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.